Skip to main content
Journal cover image

Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis

Publication ,  Conference
Buechner, J; Grupp, SA; Maude, SL; Boyer, M; Bittencourt, H; Laetsch, TW; Bader, P; Verneris, MR; Stefanski, H; Myers, GD; Qayed, M; Schlis, K ...
Published in: Clinical Lymphoma Myeloma and Leukemia
September 2017

Duke Scholars

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

September 2017

Volume

17

Start / End Page

S263 / S264

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Buechner, J., Grupp, S. A., Maude, S. L., Boyer, M., Bittencourt, H., Laetsch, T. W., … Rives, S. (2017). Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. S263–S264). Elsevier BV. https://doi.org/10.1016/j.clml.2017.07.030
Buechner, Jochen, Stephan A. Grupp, Shannon L. Maude, Michael Boyer, Henrique Bittencourt, Theodore W. Laetsch, Peter Bader, et al. “Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis.” In Clinical Lymphoma Myeloma and Leukemia, 17:S263–64. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.07.030.
Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, et al. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S263–4.
Buechner, Jochen, et al. “Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, Elsevier BV, 2017, pp. S263–64. Crossref, doi:10.1016/j.clml.2017.07.030.
Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, Bader P, Verneris MR, Stefanski H, Myers GD, Qayed M, Pulsipher MA, De Moerloose B, Hiramatsu H, Schlis K, Davis K, Martin PL, Nemecek E, Peters C, Wood P, Taran T, Mueller KT, Zhang Y, Rives S. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S263–S264.
Journal cover image

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

September 2017

Volume

17

Start / End Page

S263 / S264

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences